Opdivo nivolumab: Phase III data

The open-label, international Phase III CheckMate -017 trial in 272 patients with previously treated advanced or metastatic squamous cell NSCLC was stopped early

Read the full 232 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE